
UPB Stock Forecast & Price Target
UPB Analyst Ratings
Bulls say
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist with potential for best-in-class efficacy in treating inflammatory diseases such as nasal polyps, asthma, and COPD. The company faces financing risks, but has enough funds to last until 2027. Their stock has seen volatility due to market sentiment, but targeting the TSLP pathway shows potential for commercial success, although uncertainties and risks remain.
Bears say
Upstream Bio is developing a novel antibody antagonist, verekitug, for the treatment of inflammatory diseases, with initial focus on severe respiratory disorders. While clinical trials have shown promising results for verekitug, the stock carries significant risks, including potential need for capital raises and volatility in the biotech market. Additionally, the Phase 3 strategy for severe asthma and chronic rhinosinusitis with nasal polyps may offer differentiation, but there is uncertainty regarding the drug's potential efficacy in COPD.
This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
UPB Analyst Forecast & Price Prediction
Start investing in UPB
Order type
Buy in
Order amount
Est. shares
0 shares